Clinical Approach to Post-acute Sequelae After COVID-19 Infection and Vaccination
Nicolas Hulscher, Brian C Procter, Cade Wynn, Peter A Mccullough
Cureus, doi:10.7759/cureus.49204
The spike protein of SARS-CoV-2 has been found to exhibit pathogenic characteristics and be a possible cause of post-acute sequelae after SARS-CoV-2 infection or COVID-19 vaccination. COVID-19 vaccines utilize a modified, stabilized prefusion spike protein that may share similar toxic effects with its viral counterpart. The aim of this study is to investigate possible mechanisms of harm to biological systems from SARS-CoV-2 spike protein and vaccine-encoded spike protein and to propose possible mitigation strategies. We searched PubMed, Google Scholar, and 'grey literature' to find studies that (1) investigated the effects of the spike protein on biological systems, (2) helped differentiate between viral and vaccine-generated spike proteins, and (3) identified possible spike protein detoxification protocols and compounds that had signals of benefit and acceptable safety profiles. We found abundant evidence that SARS-CoV-2 spike protein may cause damage in the cardiovascular, hematological, neurological, respiratory, gastrointestinal, and immunological systems. Viral and vaccine-encoded spike proteins have been shown to play a direct role in cardiovascular and thrombotic injuries from both SARS-CoV-2 and vaccination. Detection of spike protein for at least 6-15 months after vaccination and infection in those with post-acute sequelae indicates spike protein as a possible primary contributing factor to long COVID. We rationalized that these findings give support to the potential benefit of spike protein detoxification protocols in those with long-term postinfection and/or vaccine-induced complications. We propose a base spike detoxification protocol, composed of oral nattokinase, bromelain, and curcumin. This approach holds immense promise as a base of clinical care, upon which additional therapeutic agents are applied with the goal of aiding in the resolution of postacute sequelae after SARS-CoV-2 infection and COVID-19 vaccination. Large-scale, prospective, randomized, double-blind, placebo-controlled trials are warranted in order to determine the relative risks and benefits of the base spike detoxification protocol.
Additional Information Author Contributions All authors have reviewed the final version to be published and agreed to be accountable for all aspects of the work.
Concept and design:
References
Ait-Belkacem, García, Millet-Wallisky, SARS-CoV-2 spike protein induces a differential monocyte activation that may contribute to age bias in COVID-19 severity, Sci Rep,
doi:10.1038/s41598-022-25259-2Akhter, Quéromès, Pillai, The combination of bromelain and acetylcysteine (Bromac) synergistically inactivates SARS-CoV-2, Viruses,
doi:10.3390/v13030425Almehdi, Khoder, Alchakee, Alsayyid, Sarg et al., SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies, Infection,
doi:10.1007/s15010-021-01677-8Avolio, Carrabba, Milligan, The SARS-CoV-2 spike protein disrupts human cardiac pericytes function through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease, Clin Sci (Lond),
doi:10.1042/CS20210735Barati, Motavallihaghi, Nikfar, Chaichian, Momtazi-Borojeni, Potential therapeutic effects of ivermectin in COVID-19, Exp Biol Med,
doi:10.1177/15353702221099579Baumeier, Aleshcheva, Harms, Intramyocardial Inflammation after COVID-19 vaccination: an endomyocardial biopsy-proven case series, Int J Mol Sci,
doi:10.3390/ijms23136940Brogna, Cristoni, Marino, Detection of recombinant Spike protein in the blood of individuals vaccinated against SARS-CoV-2: possible molecular mechanisms, Proteomics Clin Appl,
doi:10.1002/prca.202300048Chakraborty, Mitra, Tallei, Bromelain a potential bioactive compound: a comprehensive overview from a pharmacological perspective, Life,
doi:10.3390/life11040317Cheng, Hsu, Lin, Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions, Anticancer Res
Clemens, Ye, Zhou, SARS-CoV-2 spike protein-mediated cardiomyocyte fusion may contribute to increased arrhythmic risk in COVID-19, PLoS One,
doi:10.1371/journal.pone.0282151Craddock, Mahajan, Spikes, Persistent circulation of soluble and extracellular vesicle-linked Spike protein in individuals with postacute sequelae of COVID-19, J Med Virol,
doi:10.1002/jmv.28568De Michele, Amati, Leopizzi, Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients, J Hematol Oncol,
doi:10.1186/s13045-022-01329-wDebnath, Dewaker, Prabhakar, Bhattacharyya, Mandal, Conformational perturbation of SARS-CoV-2 spike protein using N-acetyl cysteine, a molecular scissor: a probable strategy to combat COVID-19, PREPRINT,
doi:10.26434/chemrxiv.12687923.v1Deore, Tran, Andrews, Ramirez, Galie, SARS-CoV-2 spike protein disrupts blood-brain barrier integrity via RhoA activation, J Neuroimmune Pharmacol,
doi:10.1007/s11481-021-10029-0Dormoy, Perotin, Gosset, Maskos, Polette et al., Nicotinic receptors as SARS-CoV-2 spike co-receptors?, Med Hypotheses,
doi:10.1016/j.mehy.2021.110741Engin, Engin, Engin, Two important controversial risk factors in SARS-CoV-2 infection: obesity and smoking, Environ Toxicol Pharmacol,
doi:10.1016/j.etap.2020.103411Espinoza, Emmady, Histology, monocytes
Finterer, Scorza, A retrospective analysis of clinically confirmed long post-COVID vaccination syndrome, J Clin Transl Res
Fiolet, Opstal, Mosterd, Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials, Eur Heart J,
doi:10.1093/eurheartj/ehab115Fontes-Dantas, Fernandes, Gutman, SARS-CoV-2 Spike protein induces TLR4-mediated long-term cognitive dysfunction recapitulating post-COVID-19 syndrome in mice, Cell Rep,
doi:10.1016/j.celrep.2023.112189Forsyth, Zhang, Bhushan, The SARS-CoV-2 S1 spike protein promotes MAPK and NF-kB activation in human lung cells and inflammatory cytokine production in human lung and intestinal epithelial cells, Microorganisms,
doi:10.3390/microorganisms10101996Grobbelaar, Venter, Vlok, SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19, Biosci Rep,
doi:10.1042/BSR20210611Hassaniazad, Eftekhar, Inchehsablagh, A triple-blind, placebo-controlled, randomized clinical trial to evaluate the effect of curcumin-containing nanomicelles on cellular immune responses subtypes and clinical outcome in COVID-19 patients, Phytother Res,
doi:10.1002/ptr.7294Hegde, Girisa, Bharathwajchetty, Vishwa, Kunnumakkara, Curcumin formulations for better bioavailability: what we learned from clinical trials thus far?, ACS Omega,
doi:10.1021/acsomega.2c07326Hulscher, Alexander, Amerling, A systematic review of autopsy findings in deaths after COVID-19 vaccination, PREPRINT,
doi:10.5281/zenodo.8120771Huynh, Rethi, Lee, Higa, Kao et al., Spike protein impairs mitochondrial function in human cardiomyocytes: mechanisms underlying cardiac injury in COVID-19, Cells,
doi:10.3390/cells12060877Karatza, Ismailos, Karalis, Colchicine for the treatment of COVID-19 patients: efficacy, safety, and model informed dosage regimens, Xenobiotica,
doi:10.1080/00498254.2021.1909782Kim, Jeon, Kim, Lee, Kim et al., Spike proteins of SARS-CoV-2 induce pathological changes in molecular delivery and metabolic function in the brain endothelial cells, Viruses,
doi:10.3390/v13102021Kritis, Karampela, Kokoris, Dalamaga, The combination of bromelain and curcumin as an immuneboosting nutraceutical in the prevention of severe COVID-19, Metabol Open,
doi:10.1016/j.metop.2020.100066Kucia, Ratajczak, Bujko, An evidence that SARS-CoV-2/COVID-19 spike protein (SP) damages hematopoietic stem/progenitor cells in the mechanism of pyroptosis in Nlrp3 inflammasome-dependent manner, Leukemia,
doi:10.1038/s41375-021-01332-zKurosawa, Nirengi, Homma, Esaki, Ohta et al., A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles, Sci Rep,
doi:10.1038/srep11601Lotz-Winter, On the pharmacology of bromelain: an update with special regard to animal studies on dosedependent effects, Planta Med,
doi:10.1055/s-2006-960949Mayordomo-Colunga, Vivanco-Allende, López-Alonso, López-Martínez, Vega et al., SARS-CoV-2 spike protein in intestinal cells of a patient with coronavirus disease 2019 multisystem inflammatory syndrome, J Pediatr,
doi:10.1016/j.jpeds.2021.11.058Mccullough, Wynn, Procter, Clinical rationale for SARS-CoV-2 base spike protein detoxification in post COVID-19 and vaccine injury syndromes, J Am Physicians Surg
Murae, Shimizu, Yamamoto, The function of SARS-CoV-2 spike protein is impaired by disulfide-bond disruption with mutation at cysteine-488 and by thiol-reactive N-acetyl-cysteine and glutathione, Biochem Biophys Res Commun,
doi:10.1016/j.bbrc.2022.01.106Nag, Banerjee, Paul, Kundu, Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study, Comput Biol Med,
doi:10.1016/j.compbiomed.2022.105552Oba, Rongduo, Saito, Natto extract, a Japanese fermented soybean food, directly inhibits viral infections including SARS-CoV-2 in vitro, Biochem Biophys Res Commun,
doi:10.1016/j.bbrc.2021.07.034Oh, Cho, Barcelon, Kim, Hong et al., SARS-CoV-2 spike protein induces cognitive deficit and anxiety-like behavior in mouse via non-cell autonomous hippocampal neuronal death, Sci Rep,
doi:10.1038/s41598-022-09410-7Omoboyowa, Balogun, Chukwudozie, SARS-CoV-2 spike glycoprotein as inhibitory target for Insilico screening of natural compounds, Biointerface Res Appl Chem,
doi:10.33263/BRIAC116.1497414985Palestra, Poto, Ciardi, SARS-CoV-2 spike protein activates human lung macrophages, Int J Mol Sci,
doi:10.3390/ijms24033036Pandey, Rane, Chatterjee, Kumar, Khan et al., Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an in silico study for drug development, J Biomol Struct Dyn,
doi:10.1080/07391102.2020.1796811Parry, Lefringhausen, Turni, Neil, Cosford et al., Spikeopathy': COVID-19 spike protein is pathogenic, from both virus and vaccine mRNA, Biomedicines,
doi:10.3390/biomedicines11082287Patel, Kaki, Potluri, Kahar, Khanna, A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson, Hum Vaccin Immunother,
doi:10.1080/21645515.2021.2002083Patterson, Francisco, Yogendra, Persistence of SARS CoV-2 S1 protein in CD16+ monocytes in post-acute sequelae of COVID-19 (PASC) up to 15 months post-infection, Front Immunol,
doi:10.3389/fimmu.2021.746021Perico, Morigi, Pezzotta, SARS-CoV-2 spike protein induces lung endothelial cell dysfunction and thrombo-inflammation depending on the C3a/C3a receptor signalling, Sci Rep,
doi:10.1038/s41598-023-38382-5Praditya, Kirchhoff, Brüning, Rachmawati, Steinmann et al., Anti-infective properties of the golden spice curcumin, Front Microbiol,
doi:10.3389/fmicb.2019.00912Rabbani, Parikh, Rafique, Colchicine for the treatment of myocardial injury in patients with coronavirus disease 2019 (COVID-19)-an old drug with new life?, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2020.13556Robles, Zamora, Castro, Siqueiros-Marquez, De La Escalera et al., The spike protein of SARS-CoV-2 induces endothelial inflammation through integrin α5β1 and NF-κB signaling, J Biol Chem,
doi:10.1016/j.jbc.2022.101695Rowan, Buttle, Barrett, The cysteine proteinases of the pineapple plant, Biochem J
Sadeghizadeh, Asadollahi, Jahangiri, Promising clinical outcomes of nano-curcumin treatment as an adjunct therapy in hospitalized COVID-19 patients: a randomized, double-blinded, placebo-controlled trial, Phytother Res,
doi:10.1002/ptr.7844Said, Al-Otaibi, Aljaloud, Al-Anazi, Alsolami et al., The frequency and patterns of post-COVID-19 vaccination syndrome reveal initially mild and potentially Immunocytopenic signs in primarily young Saudi women, Vaccines,
doi:10.3390/vaccines10071015Schroeder, Bieneman, The S1 subunit of the SARS-CoV-2 spike protein activates human monocytes to produce cytokines linked to COVID-19: relevance to galectin-3, Front Immunol,
doi:10.3389/fimmu.2022.831763Sheng, Yang, Wang, Sun, Yan, Microbial nattokinase: from synthesis to potential application, Food Funct,
doi:10.1039/d2fo03389eShrestha, Venkataraman, The prevalence of post-COVID-19 vaccination syndrome and quality of life among COVID-19-vaccinated individuals, IN PRESS,
doi:10.1016/j.vacun.2023.10.002Sogut, Can, Guven, Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: a pilot observational study, Am J Emerg Med,
doi:10.1016/j.ajem.2020.12.014Speciale, Muscarà, Molonia, Cimino, Saija et al., Silibinin as potential tool against SARS-CoV-2: in silico spike receptor-binding domain and main protease molecular docking analysis, and in vitro endothelial protective effects, Phytother Res,
doi:10.1002/ptr.7107Tardif, Bouabdallaoui, Allier, Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial, Lancet Respir Med,
doi:10.1016/S2213-2600(21)00222-8Tenório, Graciliano, Moura, Oliveira, Goulart, N-acetylcysteine (NAC): impacts on human health, Antioxidants,
doi:10.3390/antiox10060967Tuli, Sood, Pundir, Molecular docking studies of apigenin, kaempferol, and quercetin as potential target against spike receptor protein of SARS CoV, J Exp Biol Agric Sci,
doi:10.18006/2022.10(1).144.149Turner, Khan, Putrino, Woodcock, Kell et al., Long COVID: pathophysiological factors and abnormalities of coagulation, Trends Endocrinol Metab,
doi:10.1016/j.tem.2023.03.002Vettori, Dima, Henry, Effects of different types of recombinant SARS-CoV-2 spike protein on circulating monocytes' structure, Int J Mol Sci,
doi:10.3390/ijms24119373Yasmin, Najeeb, Moeed, Safety and efficacy of colchicine in COVID-19 patients: a systematic review and meta-analysis of randomized control trials, PLoS One,
doi:10.1371/journal.pone.0266245Yuan, Pavel, Wang, Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway in mammalian cell culture, Commun Biol,
doi:10.1038/s42003-022-03841-8Zeng, Li, Deng, SARS-CoV-2 spike spurs intestinal inflammation via VEGF production in enterocytes, EMBO Mol Med,
doi:10.15252/emmm.202114844Zheng, Zhao, Li, SARS-CoV-2 spike protein causes blood coagulation and thrombosis by competitive binding to heparan sulfate, Int J Biol Macromol,
doi:10.1016/j.ijbiomac.2021.10.112{ 'indexed': { 'date-parts': [[2023, 11, 22]],
'date-time': '2023-11-22T00:23:30Z',
'timestamp': 1700612610394},
'reference-count': 82,
'publisher': 'Springer Science and Business Media LLC',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'published-print': {'date-parts': [[2023, 11, 21]]},
'DOI': '10.7759/cureus.49204',
'type': 'journal-article',
'created': { 'date-parts': [[2023, 11, 21]],
'date-time': '2023-11-21T23:22:16Z',
'timestamp': 1700608936000},
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Clinical Approach to Post-acute Sequelae After COVID-19 Infection and Vaccination',
'prefix': '10.7759',
'author': [ {'given': 'Nicolas', 'family': 'Hulscher', 'sequence': 'first', 'affiliation': []},
{'given': 'Brian C', 'family': 'Procter', 'sequence': 'additional', 'affiliation': []},
{'given': 'Cade', 'family': 'Wynn', 'sequence': 'additional', 'affiliation': []},
{'given': 'Peter A', 'family': 'McCullough', 'sequence': 'additional', 'affiliation': []}],
'member': '297',
'reference': [ { 'key': 'ref1',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.heliyon.2023.e13952',
'article-title': 'An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and '
'vaccines',
'volume': '9',
'author': 'Hillary VE',
'year': '2023',
'unstructured': 'Hillary VE, Ceasar SA. An update on COVID-19: SARS-CoV-2 variants, '
'antiviral drugs, and vaccines. Heliyon. 2023, 9:e13952. '
'10.1016/j.heliyon.2023.e13952',
'journal-title': 'Heliyon'},
{ 'key': 'ref2',
'unstructured': 'WHO coronavirus (COVID-19) dashboard. (2023). Accessed. November 22, '
'2023: https://covid19.who.int/.'},
{ 'key': 'ref3',
'doi-asserted-by': 'publisher',
'DOI': '10.1080/21645515.2021.2002083',
'article-title': 'A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & '
'Johnson & Johnson',
'volume': '18',
'author': 'Patel R',
'year': '2022',
'unstructured': 'Patel R, Kaki M, Potluri VS, Kahar P, Khanna D. A comprehensive review '
'of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson. Hum '
'Vaccin Immunother. 2022, 18:2002083. 10.1080/21645515.2021.2002083',
'journal-title': 'Hum Vaccin Immunother'},
{ 'key': 'ref4',
'doi-asserted-by': 'publisher',
'DOI': '10.1007/s15010-021-01677-8',
'article-title': 'SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential '
'therapies',
'volume': '49',
'author': 'Almehdi AM',
'year': '2021',
'unstructured': 'Almehdi AM, Khoder G, Alchakee AS, Alsayyid AT, Sarg NH, Soliman SS. '
'SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential '
'therapies. Infection. 2021, 49:855-76. 10.1007/s15010-021-01677-8',
'journal-title': 'Infection'},
{ 'key': 'ref5',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41579-022-00846-2',
'article-title': 'Long COVID: major findings, mechanisms and recommendations',
'volume': '21',
'author': 'Davis HE',
'year': '2023',
'unstructured': 'Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, '
'mechanisms and recommendations. Nat Rev Microbiol. 2023, 21:133-46. '
'10.1038/s41579-022-00846-2',
'journal-title': 'Nat Rev Microbiol'},
{ 'key': 'ref6',
'article-title': 'A retrospective analysis of clinically confirmed long post-COVID '
'vaccination syndrome',
'volume': '8',
'author': 'Finterer J',
'year': '2022',
'unstructured': 'Finterer J, Scorza FA. A retrospective analysis of clinically confirmed '
'long post-COVID vaccination syndrome. J Clin Transl Res. 2022, 8:506-8.',
'journal-title': 'J Clin Transl Res'},
{ 'key': 'ref7',
'doi-asserted-by': 'publisher',
'DOI': '10.1001/jamanetworkopen.2021.28568',
'article-title': 'Short-term and long-term rates of postacute sequelae of SARS-CoV-2 '
'infection: a systematic review',
'volume': '4',
'author': 'Groff D',
'year': '2021',
'unstructured': 'Groff D, Sun A, Ssentongo AE, et al.. Short-term and long-term rates of '
'postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA '
'Netw Open. 2021, 4:e2128568. 10.1001/jamanetworkopen.2021.28568',
'journal-title': 'JAMA Netw Open'},
{ 'key': 'ref8',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.vacun.2023.10.002',
'article-title': 'The prevalence of post-COVID-19 vaccination syndrome and quality of '
'life among COVID-19-vaccinated individuals [IN PRESS]',
'author': 'Shrestha Y',
'year': '2023',
'unstructured': 'Shrestha Y, Venkataraman R. The prevalence of post-COVID-19 vaccination '
'syndrome and quality of life among COVID-19-vaccinated individuals [IN '
'PRESS]. Vacunas. 2023, 10.1016/j.vacun.2023.10.002',
'journal-title': 'Vacunas'},
{ 'key': 'ref9',
'doi-asserted-by': 'publisher',
'DOI': '10.3390/vaccines10071015',
'article-title': 'The frequency and patterns of post-COVID-19 vaccination syndrome reveal '
'initially mild and potentially Immunocytopenic signs in primarily young '
'Saudi women',
'volume': '10',
'author': 'Said KB',
'year': '2022',
'unstructured': 'Said KB, Al-Otaibi A, Aljaloud L, Al-Anazi B, Alsolami A, Alreshidi FS. '
'The frequency and patterns of post-COVID-19 vaccination syndrome reveal '
'initially mild and potentially Immunocytopenic signs in primarily young '
'Saudi women. Vaccines (Basel). 2022, 10:1015. 10.3390/vaccines10071015',
'journal-title': 'Vaccines (Basel)'},
{ 'key': 'ref10',
'doi-asserted-by': 'publisher',
'DOI': '10.1007/s12035-021-02696-0',
'article-title': 'Could SARS-CoV-2 spike protein be responsible for long-COVID syndrome?',
'volume': '59',
'author': 'Theoharides TC',
'year': '2022',
'unstructured': 'Theoharides TC. Could SARS-CoV-2 spike protein be responsible for '
'long-COVID syndrome?. Mol Neurobiol. 2022, 59:1850-61. '
'10.1007/s12035-021-02696-0',
'journal-title': 'Mol Neurobiol'},
{ 'key': 'ref11',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.tem.2023.03.002',
'article-title': 'Long COVID: pathophysiological factors and abnormalities of coagulation',
'volume': '34',
'author': 'Turner S',
'year': '2023',
'unstructured': 'Turner S, Khan MA, Putrino D, Woodcock A, Kell DB, Pretorius E. Long '
'COVID: pathophysiological factors and abnormalities of coagulation. '
'Trends Endocrinol Metab. 2023, 34:321-44. 10.1016/j.tem.2023.03.002',
'journal-title': 'Trends Endocrinol Metab'},
{ 'key': 'ref12',
'doi-asserted-by': 'publisher',
'DOI': '10.3390/biomedicines11082287',
'article-title': '‘Spikeopathy’: COVID-19 spike protein is pathogenic, from both virus '
'and vaccine mRNA',
'volume': '11',
'author': 'Parry PI',
'year': '2023',
'unstructured': 'Parry PI, Lefringhausen A, Turni C, Neil CJ, Cosford R, Hudson NJ, '
'Gillespie J. ‘Spikeopathy’: COVID-19 spike protein is pathogenic, from '
'both virus and vaccine mRNA. Biomedicines. 2023, 11:2287. '
'10.3390/biomedicines11082287',
'journal-title': 'Biomedicines'},
{ 'key': 'ref13',
'doi-asserted-by': 'publisher',
'DOI': '10.1042/CS20210735',
'article-title': 'The SARS-CoV-2 spike protein disrupts human cardiac pericytes function '
'through CD147 receptor-mediated signalling: a potential non-infective '
'mechanism of COVID-19 microvascular disease',
'volume': '135',
'author': 'Avolio E',
'year': '2021',
'unstructured': 'Avolio E, Carrabba M, Milligan R, et al.. The SARS-CoV-2 spike protein '
'disrupts human cardiac pericytes function through CD147 '
'receptor-mediated signalling: a potential non-infective mechanism of '
'COVID-19 microvascular disease. Clin Sci (Lond). 2021, 135:2667-89. '
'10.1042/CS20210735',
'journal-title': 'Clin Sci (Lond)'},
{ 'key': 'ref14',
'doi-asserted-by': 'publisher',
'DOI': '10.3390/cells12060877',
'article-title': 'Spike protein impairs mitochondrial function in human cardiomyocytes: '
'mechanisms underlying cardiac injury in COVID-19',
'volume': '12',
'author': 'Huynh TV',
'year': '2023',
'unstructured': 'Huynh TV, Rethi L, Lee TW, Higa S, Kao YH, Chen YJ. Spike protein '
'impairs mitochondrial function in human cardiomyocytes: mechanisms '
'underlying cardiac injury in COVID-19. Cells. 2023, 12:877. '
'10.3390/cells12060877',
'journal-title': 'Cells'},
{ 'key': 'ref15',
'doi-asserted-by': 'publisher',
'DOI': '10.1371/journal.pone.0282151',
'article-title': 'SARS-CoV-2 spike protein-mediated cardiomyocyte fusion may contribute '
'to increased arrhythmic risk in COVID-19',
'volume': '18',
'author': 'Clemens DJ',
'year': '2023',
'unstructured': 'Clemens DJ, Ye D, Zhou W, et al.. SARS-CoV-2 spike protein-mediated '
'cardiomyocyte fusion may contribute to increased arrhythmic risk in '
'COVID-19. PLoS One. 2023, 18:e0282151. 10.1371/journal.pone.0282151',
'journal-title': 'PLoS One'},
{ 'key': 'ref16',
'doi-asserted-by': 'publisher',
'DOI': '10.1161/CIRCULATIONAHA.122.061025',
'article-title': 'Circulating spike protein detected in post-COVID-19 mRNA vaccine '
'myocarditis',
'volume': '147',
'author': 'Yonker LM',
'year': '2023',
'unstructured': 'Yonker LM, Swank Z, Bartsch YC, et al.. Circulating spike protein '
'detected in post-COVID-19 mRNA vaccine myocarditis. Circulation. 2023, '
'147:867-76. 10.1161/CIRCULATIONAHA.122.061025',
'journal-title': 'Circulation'},
{ 'key': 'ref17',
'doi-asserted-by': 'publisher',
'DOI': '10.3390/ijms23136940',
'article-title': 'Intramyocardial Inflammation after COVID-19 vaccination: an '
'endomyocardial biopsy-proven case series',
'volume': '23',
'author': 'Baumeier C',
'year': '2022',
'unstructured': 'Baumeier C, Aleshcheva G, Harms D, et al.. Intramyocardial Inflammation '
'after COVID-19 vaccination: an endomyocardial biopsy-proven case series. '
'Int J Mol Sci. 2022, 23:6940. 10.3390/ijms23136940',
'journal-title': 'Int J Mol Sci'},
{ 'key': 'ref18',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.jbc.2022.101695',
'article-title': 'The spike protein of SARS-CoV-2 induces endothelial inflammation '
'through integrin α5β1 and NF-κB signaling',
'volume': '298',
'author': 'Robles JP',
'year': '2022',
'unstructured': 'Robles JP, Zamora M, Adan-Castro E, Siqueiros-Marquez L, Martinez de la '
'Escalera G, Clapp C. The spike protein of SARS-CoV-2 induces endothelial '
'inflammation through integrin α5β1 and NF-κB signaling. J Biol Chem. '
'2022, 298:101695. 10.1016/j.jbc.2022.101695',
'journal-title': 'J Biol Chem'},
{ 'key': 'ref19',
'doi-asserted-by': 'publisher',
'DOI': '10.1042/BSR20210611',
'article-title': 'SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to '
'fibrinolysis: implications for microclot formation in COVID-19',
'volume': '41',
'author': 'Grobbelaar LM',
'year': '2021',
'unstructured': 'Grobbelaar LM, Venter C, Vlok M, et al.. SARS-CoV-2 spike protein S1 '
'induces fibrin(ogen) resistant to fibrinolysis: implications for '
'microclot formation in COVID-19. Biosci Rep. 2021, 41:BSR20210611. '
'10.1042/BSR20210611',
'journal-title': 'Biosci Rep'},
{ 'key': 'ref20',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.ijbiomac.2021.10.112',
'article-title': 'SARS-CoV-2 spike protein causes blood coagulation and thrombosis by '
'competitive binding to heparan sulfate',
'volume': '193',
'author': 'Zheng Y',
'year': '2021',
'unstructured': 'Zheng Y, Zhao J, Li J, et al.. SARS-CoV-2 spike protein causes blood '
'coagulation and thrombosis by competitive binding to heparan sulfate. '
'Int J Biol Macromol. 2021, 193:1124-9. 10.1016/j.ijbiomac.2021.10.112',
'journal-title': 'Int J Biol Macromol'},
{ 'key': 'ref21',
'doi-asserted-by': 'publisher',
'DOI': '10.1186/s13045-022-01329-w',
'article-title': 'Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 '
'patients',
'volume': '15',
'author': 'De Michele M',
'year': '2022',
'unstructured': "De Michele M, d'Amati G, Leopizzi M, et al.. Evidence of SARS-CoV-2 "
'spike protein on retrieved thrombi from COVID-19 patients. J Hematol '
'Oncol. 2022, 15:108. 10.1186/s13045-022-01329-w',
'journal-title': 'J Hematol Oncol'},
{ 'key': 'ref22',
'doi-asserted-by': 'publisher',
'DOI': '10.1007/s11481-021-10029-0',
'article-title': 'SARS-CoV-2 spike protein disrupts blood-brain barrier integrity via '
'RhoA activation',
'volume': '16',
'author': 'DeOre BJ',
'year': '2021',
'unstructured': 'DeOre BJ, Tran KA, Andrews AM, Ramirez SH, Galie PA. SARS-CoV-2 spike '
'protein disrupts blood-brain barrier integrity via RhoA activation. J '
'Neuroimmune Pharmacol. 2021, 16:722-8. 10.1007/s11481-021-10029-0',
'journal-title': 'J Neuroimmune Pharmacol'},
{ 'key': 'ref23',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41598-022-09410-7',
'article-title': 'SARS-CoV-2 spike protein induces cognitive deficit and anxiety-like '
'behavior in mouse via non-cell autonomous hippocampal neuronal death',
'volume': '12',
'author': 'Oh J',
'year': '2022',
'unstructured': 'Oh J, Cho WH, Barcelon E, Kim KH, Hong J, Lee SJ. SARS-CoV-2 spike '
'protein induces cognitive deficit and anxiety-like behavior in mouse via '
'non-cell autonomous hippocampal neuronal death. Sci Rep. 2022, 12:5496. '
'10.1038/s41598-022-09410-7',
'journal-title': 'Sci Rep'},
{ 'key': 'ref24',
'doi-asserted-by': 'publisher',
'DOI': '10.3390/v13102021',
'article-title': 'Spike proteins of SARS-CoV-2 induce pathological changes in molecular '
'delivery and metabolic function in the brain endothelial cells',
'volume': '13',
'author': 'Kim ES',
'year': '2021',
'unstructured': 'Kim ES, Jeon MT, Kim KS, Lee S, Kim S, Kim DG. Spike proteins of '
'SARS-CoV-2 induce pathological changes in molecular delivery and '
'metabolic function in the brain endothelial cells. Viruses. 2021, '
'13:2021. 10.3390/v13102021',
'journal-title': 'Viruses'},
{ 'key': 'ref25',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.celrep.2023.112189',
'article-title': 'SARS-CoV-2 Spike protein induces TLR4-mediated long-term cognitive '
'dysfunction recapitulating post-COVID-19 syndrome in mice',
'volume': '42',
'author': 'Fontes-Dantas FL',
'year': '2023',
'unstructured': 'Fontes-Dantas FL, Fernandes GG, Gutman EG, et al.. SARS-CoV-2 Spike '
'protein induces TLR4-mediated long-term cognitive dysfunction '
'recapitulating post-COVID-19 syndrome in mice. Cell Rep. 2023, '
'42:112189. 10.1016/j.celrep.2023.112189',
'journal-title': 'Cell Rep'},
{ 'key': 'ref26',
'doi-asserted-by': 'publisher',
'DOI': '10.3390/microorganisms10101996',
'article-title': 'The SARS-CoV-2 S1 spike protein promotes MAPK and NF-kB activation in '
'human lung cells and inflammatory cytokine production in human lung and '
'intestinal epithelial cells',
'volume': '10',
'author': 'Forsyth CB',
'year': '2022',
'unstructured': 'Forsyth CB, Zhang L, Bhushan A, et al.. The SARS-CoV-2 S1 spike protein '
'promotes MAPK and NF-kB activation in human lung cells and inflammatory '
'cytokine production in human lung and intestinal epithelial cells. '
'Microorganisms. 2022, 10:1996. 10.3390/microorganisms10101996',
'journal-title': 'Microorganisms'},
{ 'key': 'ref27',
'doi-asserted-by': 'publisher',
'DOI': '10.3390/ijms24033036',
'article-title': 'SARS-CoV-2 spike protein activates human lung macrophages',
'volume': '24',
'author': 'Palestra F',
'year': '2023',
'unstructured': 'Palestra F, Poto R, Ciardi R, et al.. SARS-CoV-2 spike protein activates '
'human lung macrophages. Int J Mol Sci. 2023, 24:3036. '
'10.3390/ijms24033036',
'journal-title': 'Int J Mol Sci'},
{ 'key': 'ref28',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41598-023-38382-5',
'article-title': 'SARS-CoV-2 spike protein induces lung endothelial cell dysfunction and '
'thrombo-inflammation depending on the C3a/C3a receptor signalling',
'volume': '13',
'author': 'Perico L',
'year': '2023',
'unstructured': 'Perico L, Morigi M, Pezzotta A, et al.. SARS-CoV-2 spike protein induces '
'lung endothelial cell dysfunction and thrombo-inflammation depending on '
'the C3a/C3a receptor signalling. Sci Rep. 2023, 13:11392. '
'10.1038/s41598-023-38382-5',
'journal-title': 'Sci Rep'},
{ 'key': 'ref29',
'doi-asserted-by': 'publisher',
'DOI': '10.15252/emmm.202114844',
'article-title': 'SARS-CoV-2 spike spurs intestinal inflammation via VEGF production in '
'enterocytes',
'volume': '14',
'author': 'Zeng FM',
'year': '2022',
'unstructured': 'Zeng FM, Li YW, Deng ZH, et al.. SARS-CoV-2 spike spurs intestinal '
'inflammation via VEGF production in enterocytes. EMBO Mol Med. 2022, '
'14:e14844. 10.15252/emmm.202114844',
'journal-title': 'EMBO Mol Med'},
{ 'key': 'ref30',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.jpeds.2021.11.058',
'article-title': 'SARS-CoV-2 spike protein in intestinal cells of a patient with '
'coronavirus disease 2019 multisystem inflammatory syndrome',
'volume': '243',
'author': 'Mayordomo-Colunga J',
'year': '2022',
'unstructured': 'Mayordomo-Colunga J, Vivanco-Allende A, López-Alonso I, López-Martínez '
'C, Fernández-Vega I, Gil-Peña H, Rey C. SARS-CoV-2 spike protein in '
'intestinal cells of a patient with coronavirus disease 2019 multisystem '
'inflammatory syndrome. J Pediatr. 2022, 243:214-218.e5. '
'10.1016/j.jpeds.2021.11.058',
'journal-title': 'J Pediatr'},
{ 'key': 'ref31',
'article-title': 'Histology, monocytes',
'author': 'Espinoza VE',
'year': '2023',
'unstructured': 'Espinoza VE, Emmady PD. Histology, monocytes. StatPearls. StatPearls '
'Publishing, Treasure Island, FL; 2023.'},
{ 'key': 'ref32',
'doi-asserted-by': 'publisher',
'DOI': '10.3390/ijms24119373',
'article-title': 'Effects of different types of recombinant SARS-CoV-2 spike protein on '
'circulating monocytes’ structure',
'volume': '24',
'author': 'Vettori M',
'year': '2023',
'unstructured': 'Vettori M, Dima F, Henry BM, et al.. Effects of different types of '
'recombinant SARS-CoV-2 spike protein on circulating monocytes’ '
'structure. Int J Mol Sci. 2023, 24:9373. 10.3390/ijms24119373',
'journal-title': 'Int J Mol Sci'},
{ 'key': 'ref33',
'doi-asserted-by': 'publisher',
'DOI': '10.3389/fimmu.2022.831763',
'article-title': 'The S1 subunit of the SARS-CoV-2 spike protein activates human '
'monocytes to produce cytokines linked to COVID-19: relevance to '
'galectin-3',
'volume': '13',
'author': 'Schroeder JT',
'year': '2022',
'unstructured': 'Schroeder JT, Bieneman AP. The S1 subunit of the SARS-CoV-2 spike '
'protein activates human monocytes to produce cytokines linked to '
'COVID-19: relevance to galectin-3. Front Immunol. 2022, 13:831763. '
'10.3389/fimmu.2022.831763',
'journal-title': 'Front Immunol'},
{ 'key': 'ref34',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41598-022-25259-2',
'article-title': 'SARS-CoV-2 spike protein induces a differential monocyte activation '
'that may contribute to age bias in COVID-19 severity',
'volume': '12',
'author': 'Ait-Belkacem I',
'year': '2022',
'unstructured': 'Ait-Belkacem I, Cartagena García C, Millet-Wallisky E, et al.. '
'SARS-CoV-2 spike protein induces a differential monocyte activation that '
'may contribute to age bias in COVID-19 severity. Sci Rep. 2022, '
'12:20824. 10.1038/s41598-022-25259-2',
'journal-title': 'Sci Rep'},
{ 'key': 'ref35',
'doi-asserted-by': 'publisher',
'DOI': '10.3389/fimmu.2021.746021',
'article-title': 'Persistence of SARS CoV-2 S1 protein in CD16+ monocytes in post-acute '
'sequelae of COVID-19 (PASC) up to 15 months post-infection',
'volume': '12',
'author': 'Patterson BK',
'year': '2021',
'unstructured': 'Patterson BK, Francisco EB, Yogendra R, et al.. Persistence of SARS '
'CoV-2 S1 protein in CD16+ monocytes in post-acute sequelae of COVID-19 '
'(PASC) up to 15 months post-infection. Front Immunol. 2021, 12:746021. '
'10.3389/fimmu.2021.746021',
'journal-title': 'Front Immunol'},
{ 'key': 'ref36',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41375-021-01332-z',
'article-title': 'An evidence that SARS-CoV-2/COVID-19 spike protein (SP) damages '
'hematopoietic stem/progenitor cells in the mechanism of pyroptosis in '
'Nlrp3 inflammasome-dependent manner',
'volume': '35',
'author': 'Kucia M',
'year': '2021',
'unstructured': 'Kucia M, Ratajczak J, Bujko K, et al.. An evidence that '
'SARS-CoV-2/COVID-19 spike protein (SP) damages hematopoietic '
'stem/progenitor cells in the mechanism of pyroptosis in Nlrp3 '
'inflammasome-dependent manner. Leukemia. 2021, 35:3026-9. '
'10.1038/s41375-021-01332-z',
'journal-title': 'Leukemia'},
{ 'key': 'ref37',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41586-020-2622-0',
'article-title': 'SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen '
'preparedness',
'volume': '586',
'author': 'Corbett KS',
'year': '2020',
'unstructured': 'Corbett KS, Edwards DK, Leist SR, et al.. SARS-CoV-2 mRNA vaccine design '
'enabled by prototype pathogen preparedness. Nature. 2020, 586:567-71. '
'10.1038/s41586-020-2622-0',
'journal-title': 'Nature'},
{ 'key': 'ref38',
'doi-asserted-by': 'publisher',
'DOI': '10.1126/science.abb2507',
'article-title': 'Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation',
'volume': '367',
'author': 'Wrapp D',
'year': '2020',
'unstructured': 'Wrapp D, Wang N, Corbett KS, et al.. Cryo-EM structure of the 2019-nCoV '
'spike in the prefusion conformation. Science. 2020, 367:1260-3. '
'10.1126/science.abb2507',
'journal-title': 'Science'},
{ 'key': 'ref39',
'doi-asserted-by': 'publisher',
'DOI': '10.1002/prca.202300048',
'article-title': 'Detection of recombinant Spike protein in the blood of individuals '
'vaccinated against SARS-CoV-2: possible molecular mechanisms',
'author': 'Brogna C',
'year': '2023',
'unstructured': 'Brogna C, Cristoni S, Marino G, et al.. Detection of recombinant Spike '
'protein in the blood of individuals vaccinated against SARS-CoV-2: '
'possible molecular mechanisms. Proteomics Clin Appl. 2023, e2300048. '
'10.1002/prca.202300048',
'journal-title': 'Proteomics Clin Appl'},
{ 'key': 'ref40',
'doi-asserted-by': 'publisher',
'DOI': '10.1002/jmv.28568',
'article-title': 'Persistent circulation of soluble and extracellular vesicle-linked '
'Spike protein in individuals with postacute sequelae of COVID-19',
'volume': '95',
'author': 'Craddock V',
'year': '2023',
'unstructured': 'Craddock V, Mahajan A, Spikes L, et al.. Persistent circulation of '
'soluble and extracellular vesicle-linked Spike protein in individuals '
'with postacute sequelae of COVID-19. J Med Virol. 2023, 95:e28568. '
'10.1002/jmv.28568',
'journal-title': 'J Med Virol'},
{ 'key': 'ref41',
'doi-asserted-by': 'publisher',
'DOI': '10.5281/zenodo.8120771',
'article-title': 'A systematic review of autopsy findings in deaths after COVID-19 '
'vaccination [PREPRINT]',
'author': 'Hulscher N',
'year': '2023',
'unstructured': 'Hulscher N, Alexander P, Amerling R, et al.. A systematic review of '
'autopsy findings in deaths after COVID-19 vaccination [PREPRINT]. '
'Zenodo. 2023, 10.5281/zenodo.8120771',
'journal-title': 'Zenodo'},
{ 'key': 'ref42',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.ajem.2020.09.065',
'article-title': 'Thrombotic complications of COVID-19',
'volume': '39',
'author': 'Avila J',
'year': '2021',
'unstructured': 'Avila J, Long B, Holladay D, Gottlieb M. Thrombotic complications of '
'COVID-19. Am J Emerg Med. 2021, 39:213-8. 10.1016/j.ajem.2020.09.065',
'journal-title': 'Am J Emerg Med'},
{ 'key': 'ref43',
'article-title': 'Clinical rationale for SARS-CoV-2 base spike protein detoxification in '
'post COVID-19 and vaccine injury syndromes',
'volume': '28',
'author': 'McCullough PA',
'year': '2023',
'unstructured': 'McCullough PA, Wynn C, Procter BC. Clinical rationale for SARS-CoV-2 '
'base spike protein detoxification in post COVID-19 and vaccine injury '
'syndromes. J Am Physicians Surg. 2023, 28:90-3.',
'journal-title': 'J Am Physicians Surg'},
{ 'key': 'ref44',
'doi-asserted-by': 'publisher',
'DOI': '10.1039/d2fo03389e',
'article-title': 'Microbial nattokinase: from synthesis to potential application',
'volume': '14',
'author': 'Sheng Y',
'year': '2023',
'unstructured': 'Sheng Y, Yang J, Wang C, Sun X, Yan L. Microbial nattokinase: from '
'synthesis to potential application. Food Funct. 2023, 14:2568-85. '
'10.1039/d2fo03389e',
'journal-title': 'Food Funct'},
{ 'key': 'ref45',
'doi-asserted-by': 'publisher',
'DOI': '10.1007/s00253-014-6135-3',
'article-title': 'Nattokinase: production and application',
'volume': '98',
'author': 'Dabbagh F',
'year': '2014',
'unstructured': 'Dabbagh F, Negahdaripour M, Berenjian A, et al.. Nattokinase: production '
'and application. Appl Microbiol Biotechnol. 2014, 98:9199-206. '
'10.1007/s00253-014-6135-3',
'journal-title': 'Appl Microbiol Biotechnol'},
{ 'key': 'ref46',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.bbrc.2021.07.034',
'article-title': 'Natto extract, a Japanese fermented soybean food, directly inhibits '
'viral infections including SARS-CoV-2 in\xa0vitro',
'volume': '570',
'author': 'Oba M',
'year': '2021',
'unstructured': 'Oba M, Rongduo W, Saito A, et al.. Natto extract, a Japanese fermented '
'soybean food, directly inhibits viral infections including SARS-CoV-2 '
'in\xa0vitro. Biochem Biophys Res Commun. 2021, 570:21-5. '
'10.1016/j.bbrc.2021.07.034',
'journal-title': 'Biochem Biophys Res Commun'},
{ 'key': 'ref47',
'doi-asserted-by': 'publisher',
'DOI': '10.3390/molecules27175405',
'article-title': 'Degradative effect of nattokinase on spike protein of SARS-CoV-2',
'volume': '27',
'author': 'Tanikawa T',
'year': '2022',
'unstructured': 'Tanikawa T, Kiba Y, Yu J, et al.. Degradative effect of nattokinase on '
'spike protein of SARS-CoV-2. Molecules. 2022, 27:5405. '
'10.3390/molecules27175405',
'journal-title': 'Molecules'},
{ 'key': 'ref48',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/srep11601',
'article-title': 'A single-dose of oral nattokinase potentiates thrombolysis and '
'anti-coagulation profiles',
'volume': '5',
'author': 'Kurosawa Y',
'year': '2015',
'unstructured': 'Kurosawa Y, Nirengi S, Homma T, Esaki K, Ohta M, Clark JF, Hamaoka T. A '
'single-dose of oral nattokinase potentiates thrombolysis and '
'anti-coagulation profiles. Sci Rep. 2015, 5:11601. 10.1038/srep11601',
'journal-title': 'Sci Rep'},
{ 'key': 'ref49',
'article-title': 'The cysteine proteinases of the pineapple plant',
'volume': '266',
'author': 'Rowan AD',
'year': '1990',
'unstructured': 'Rowan AD, Buttle DJ, Barrett AJ. The cysteine proteinases of the '
'pineapple plant. Biochem J. 1990, 266:869-75.',
'journal-title': 'Biochem J'},
{ 'key': 'ref50',
'doi-asserted-by': 'publisher',
'DOI': '10.1055/s-2006-960949',
'article-title': 'On the pharmacology of bromelain: an update with special regard to '
'animal studies on dose-dependent effects',
'volume': '56',
'author': 'Lotz-Winter H',
'year': '1990',
'unstructured': 'Lotz-Winter H. On the pharmacology of bromelain: an update with special '
'regard to animal studies on dose-dependent effects. Planta Med. 1990, '
'56:249-53. 10.1055/s-2006-960949',
'journal-title': 'Planta Med'},
{ 'key': 'ref51',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.metop.2020.100066',
'article-title': 'The combination of bromelain and curcumin as an immune-boosting '
'nutraceutical in the prevention of severe COVID-19',
'volume': '8',
'author': 'Kritis P',
'year': '2020',
'unstructured': 'Kritis P, Karampela I, Kokoris S, Dalamaga M. The combination of '
'bromelain and curcumin as an immune-boosting nutraceutical in the '
'prevention of severe COVID-19. Metabol Open. 2020, 8:100066. '
'10.1016/j.metop.2020.100066',
'journal-title': 'Metabol Open'},
{ 'key': 'ref52',
'doi-asserted-by': 'publisher',
'DOI': '10.3390/v13030425',
'article-title': 'The combination of bromelain and acetylcysteine (Bromac) '
'synergistically inactivates SARS-CoV-2',
'volume': '13',
'author': 'Akhter J',
'year': '2021',
'unstructured': 'Akhter J, Quéromès G, Pillai K, et al.. The combination of bromelain and '
'acetylcysteine (Bromac) synergistically inactivates SARS-CoV-2. Viruses. '
'2021, 13:425. 10.3390/v13030425',
'journal-title': 'Viruses'},
{ 'key': 'ref53',
'doi-asserted-by': 'publisher',
'DOI': '10.1007/PL00000936',
'article-title': 'Bromelain: biochemistry, pharmacology and medical use',
'volume': '58',
'author': 'Maurer HR',
'year': '2001',
'unstructured': 'Maurer HR. Bromelain: biochemistry, pharmacology and medical use. Cell '
'Mol Life Sci. 2001, 58:1234-45. 10.1007/PL00000936',
'journal-title': 'Cell Mol Life Sci'},
{ 'key': 'ref54',
'doi-asserted-by': 'publisher',
'DOI': '10.3390/life11040317',
'article-title': 'Bromelain a potential bioactive compound: a comprehensive overview from '
'a pharmacological perspective',
'volume': '11',
'author': 'Chakraborty AJ',
'year': '2021',
'unstructured': 'Chakraborty AJ, Mitra S, Tallei TE, et al.. Bromelain a potential '
'bioactive compound: a comprehensive overview from a pharmacological '
'perspective. Life (Basel). 2021, 11:317. 10.3390/life11040317',
'journal-title': 'Life (Basel)'},
{ 'key': 'ref55',
'doi-asserted-by': 'publisher',
'DOI': '10.3389/fmicb.2019.00912',
'article-title': 'Anti-infective properties of the golden spice curcumin',
'volume': '10',
'author': 'Praditya D',
'year': '2019',
'unstructured': 'Praditya D, Kirchhoff L, Brüning J, Rachmawati H, Steinmann J, Steinmann '
'E. Anti-infective properties of the golden spice curcumin. Front '
'Microbiol. 2019, 10:912. 10.3389/fmicb.2019.00912',
'journal-title': 'Front Microbiol'},
{ 'key': 'ref56',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.ejphar.2020.173551',
'article-title': 'Curcumin, a traditional spice component, can hold the promise against '
'COVID-19?',
'volume': '886',
'author': 'Soni VK',
'year': '2020',
'unstructured': 'Soni VK, Mehta A, Ratre YK, et al.. Curcumin, a traditional spice '
'component, can hold the promise against COVID-19?. Eur J Pharmacol. '
'2020, 886:173551. 10.1016/j.ejphar.2020.173551',
'journal-title': 'Eur J Pharmacol'},
{ 'key': 'ref57',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.compbiomed.2022.105552',
'article-title': 'Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern '
'(VOC) Omicron, an in silico study',
'volume': '146',
'author': 'Nag A',
'year': '2022',
'unstructured': 'Nag A, Banerjee R, Paul S, Kundu R. Curcumin inhibits spike protein of '
'new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study. '
'Comput Biol Med. 2022, 146:105552. 10.1016/j.compbiomed.2022.105552',
'journal-title': 'Comput Biol Med'},
{ 'key': 'ref58',
'doi-asserted-by': 'publisher',
'DOI': '10.1002/ptr.7844',
'article-title': 'Promising clinical outcomes of nano-curcumin treatment as an adjunct '
'therapy in hospitalized COVID-19 patients: a randomized, '
'double-blinded, placebo-controlled trial',
'volume': '37',
'author': 'Sadeghizadeh M',
'year': '2023',
'unstructured': 'Sadeghizadeh M, Asadollahi E, Jahangiri B, et al.. Promising clinical '
'outcomes of nano-curcumin treatment as an adjunct therapy in '
'hospitalized COVID-19 patients: a randomized, double-blinded, '
'placebo-controlled trial. Phytother Res. 2023, 37:3631-44. '
'10.1002/ptr.7844',
'journal-title': 'Phytother Res'},
{ 'key': 'ref59',
'doi-asserted-by': 'publisher',
'DOI': '10.1002/ptr.7294',
'article-title': 'A triple-blind, placebo-controlled, randomized clinical trial to '
'evaluate the effect of curcumin-containing nanomicelles on cellular '
'immune responses subtypes and clinical outcome in COVID-19 patients',
'volume': '35',
'author': 'Hassaniazad M',
'year': '2021',
'unstructured': 'Hassaniazad M, Eftekhar E, Inchehsablagh BR, et al.. A triple-blind, '
'placebo-controlled, randomized clinical trial to evaluate the effect of '
'curcumin-containing nanomicelles on cellular immune responses subtypes '
'and clinical outcome in COVID-19 patients. Phytother Res. 2021, '
'35:6417-27. 10.1002/ptr.7294',
'journal-title': 'Phytother Res'},
{ 'key': 'ref60',
'article-title': 'Phase I clinical trial of curcumin, a chemopreventive agent, in '
'patients with high-risk or pre-malignant lesions',
'volume': '21',
'author': 'Cheng AL',
'year': '2001',
'unstructured': 'Cheng AL, Hsu CH, Lin JK, et al.. Phase I clinical trial of curcumin, a '
'chemopreventive agent, in patients with high-risk or pre-malignant '
'lesions. Anticancer Res. 2001, 21:2895-900.',
'journal-title': 'Anticancer Res'},
{ 'key': 'ref61',
'doi-asserted-by': 'publisher',
'DOI': '10.1021/acsomega.2c07326',
'article-title': 'Curcumin formulations for better bioavailability: what we learned from '
'clinical trials thus far?',
'volume': '8',
'author': 'Hegde M',
'year': '2023',
'unstructured': 'Hegde M, Girisa S, BharathwajChetty B, Vishwa R, Kunnumakkara AB. '
'Curcumin formulations for better bioavailability: what we learned from '
'clinical trials thus far?. ACS Omega. 2023, 8:10713-46. '
'10.1021/acsomega.2c07326',
'journal-title': 'ACS Omega'},
{ 'key': 'ref62',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s42003-022-03841-8',
'article-title': 'Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway '
'in mammalian cell culture',
'volume': '5',
'author': 'Yuan Z',
'year': '2022',
'unstructured': 'Yuan Z, Pavel MA, Wang H, et al.. Hydroxychloroquine blocks SARS-CoV-2 '
'entry into the endocytic pathway in mammalian cell culture. Commun Biol. '
'2022, 5:958. 10.1038/s42003-022-03841-8',
'journal-title': 'Commun Biol'},
{ 'key': 'ref63',
'unstructured': 'HCQ for COVID-19. real-time meta analysis of 413 studies. (2023). '
'Accessed: November 4, 2023: https://c19hcq.org/meta.html.'},
{ 'key': 'ref64',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.ajem.2020.12.014',
'article-title': 'Safety and efficacy of hydroxychloroquine in 152 outpatients with '
'confirmed COVID-19: a pilot observational study',
'volume': '40',
'author': 'Sogut O',
'year': '2021',
'unstructured': 'Sogut O, Can MM, Guven R, et al.. Safety and efficacy of '
'hydroxychloroquine in 152 outpatients with confirmed COVID-19: a pilot '
'observational study. Am J Emerg Med. 2021, 40:41-6. '
'10.1016/j.ajem.2020.12.014',
'journal-title': 'Am J Emerg Med'},
{ 'key': 'ref65',
'doi-asserted-by': 'publisher',
'DOI': '10.1080/00498254.2021.1909782',
'article-title': 'Colchicine for the treatment of COVID-19 patients: efficacy, safety, '
'and model informed dosage regimens',
'volume': '51',
'author': 'Karatza E',
'year': '2021',
'unstructured': 'Karatza E, Ismailos G, Karalis V. Colchicine for the treatment of '
'COVID-19 patients: efficacy, safety, and model informed dosage regimens. '
'Xenobiotica. 2021, 51:643-56. 10.1080/00498254.2021.1909782',
'journal-title': 'Xenobiotica'},
{ 'key': 'ref66',
'doi-asserted-by': 'publisher',
'DOI': '10.1093/eurheartj/ehab115',
'article-title': 'Efficacy and safety of low-dose colchicine in patients with coronary '
'disease: a systematic review and meta-analysis of randomized trials',
'volume': '42',
'author': 'Fiolet AT',
'year': '2021',
'unstructured': 'Fiolet AT, Opstal TS, Mosterd A, et al.. Efficacy and safety of low-dose '
'colchicine in patients with coronary disease: a systematic review and '
'meta-analysis of randomized trials. Eur Heart J. 2021, 42:2765-75. '
'10.1093/eurheartj/ehab115',
'journal-title': 'Eur Heart J'},
{ 'key': 'ref67',
'doi-asserted-by': 'publisher',
'DOI': '10.1001/jamanetworkopen.2020.13556',
'article-title': 'Colchicine for the treatment of myocardial injury in patients with '
'coronavirus disease 2019 (COVID-19)—an old drug with new life?',
'volume': '3',
'author': 'Rabbani AB',
'year': '2020',
'unstructured': 'Rabbani AB, Parikh RV, Rafique AM. Colchicine for the treatment of '
'myocardial injury in patients with coronavirus disease 2019 '
'(COVID-19)—an old drug with new life?. JAMA Netw Open. 2020, 3:e2013556. '
'10.1001/jamanetworkopen.2020.13556',
'journal-title': 'JAMA Netw Open'},
{ 'key': 'ref68',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.chest.2022.08.2056',
'article-title': 'A rare case of pleurodynia after the COVID-19 vaccine',
'volume': '162',
'author': 'Ajala O',
'year': '2022',
'unstructured': 'Ajala O, Azhar A, Kalaji W, et al.. A rare case of pleurodynia after the '
'COVID-19 vaccine. Chest. 2022, 162:A2508-9. 10.1016/j.chest.2022.08.2056',
'journal-title': 'Chest'},
{ 'key': 'ref69',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/S2213-2600(21)00222-8',
'article-title': 'Colchicine for community-treated patients with COVID-19 (COLCORONA): a '
'phase 3, randomised, double-blinded, adaptive, placebo-controlled, '
'multicentre trial',
'volume': '9',
'author': 'Tardif JC',
'year': '2021',
'unstructured': "Tardif JC, Bouabdallaoui N, L'Allier PL, et al.. Colchicine for "
'community-treated patients with COVID-19 (COLCORONA): a phase 3, '
'randomised, double-blinded, adaptive, placebo-controlled, multicentre '
'trial. Lancet Respir Med. 2021, 9:924-32. 10.1016/S2213-2600(21)00222-8',
'journal-title': 'Lancet Respir Med'},
{ 'key': 'ref70',
'doi-asserted-by': 'publisher',
'DOI': '10.1371/journal.pone.0266245',
'article-title': 'Safety and efficacy of colchicine in COVID-19 patients: a systematic '
'review and meta-analysis of randomized control trials',
'volume': '17',
'author': 'Yasmin F',
'year': '2022',
'unstructured': 'Yasmin F, Najeeb H, Moeed A, et al.. Safety and efficacy of colchicine '
'in COVID-19 patients: a systematic review and meta-analysis of '
'randomized control trials. PLoS One. 2022, 17:e0266245. '
'10.1371/journal.pone.0266245',
'journal-title': 'PLoS One'},
{ 'key': 'ref71',
'doi-asserted-by': 'publisher',
'DOI': '10.26434/chemrxiv.12687923.v1',
'article-title': 'Conformational perturbation of SARS-CoV-2 spike protein using N-acetyl '
'cysteine, a molecular scissor: a probable strategy to combat COVID-19 '
'[PREPRINT]',
'author': 'Debnath U',
'year': '2021',
'unstructured': 'Debnath U, Dewaker V, Prabhakar YS, Bhattacharyya P, Mandal A. '
'Conformational perturbation of SARS-CoV-2 spike protein using N-acetyl '
'cysteine, a molecular scissor: a probable strategy to combat COVID-19 '
'[PREPRINT]. ChemRxiv. 2021, 10.26434/chemrxiv.12687923.v1',
'journal-title': 'ChemRxiv'},
{ 'key': 'ref72',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.bbrc.2022.01.106',
'article-title': 'The function of SARS-CoV-2 spike protein is impaired by disulfide-bond '
'disruption with mutation at cysteine-488 and by thiol-reactive '
'N-acetyl-cysteine and glutathione',
'volume': '597',
'author': 'Murae M',
'year': '2022',
'unstructured': 'Murae M, Shimizu Y, Yamamoto Y, et al.. The function of SARS-CoV-2 spike '
'protein is impaired by disulfide-bond disruption with mutation at '
'cysteine-488 and by thiol-reactive N-acetyl-cysteine and glutathione. '
'Biochem Biophys Res Commun. 2022, 597:30-6. 10.1016/j.bbrc.2022.01.106',
'journal-title': 'Biochem Biophys Res Commun'},
{ 'key': 'ref73',
'doi-asserted-by': 'publisher',
'DOI': '10.1177/15353702221099579',
'article-title': 'Potential therapeutic effects of ivermectin in COVID-19',
'volume': '247',
'author': 'Barati N',
'year': '2022',
'unstructured': 'Barati N, Motavallihaghi S, Nikfar B, Chaichian S, Momtazi-Borojeni AA. '
'Potential therapeutic effects of ivermectin in COVID-19. Exp Biol Med '
'(Maywood). 2022, 247:1388-96. 10.1177/15353702221099579',
'journal-title': 'Exp Biol Med (Maywood)'},
{ 'key': 'ref74',
'doi-asserted-by': 'publisher',
'DOI': '10.18006/2022.10(1).144.149',
'article-title': 'Molecular docking studies of apigenin, kaempferol, and quercetin as '
'potential target against spike receptor protein of SARS CoV',
'volume': '10',
'author': 'Tuli H',
'year': '2022',
'unstructured': 'Tuli H, Sood S, Pundir A, et al.. Molecular docking studies of apigenin, '
'kaempferol, and quercetin as potential target against spike receptor '
'protein of SARS CoV. J Exp Biol Agric Sci. 2022, 10:144-9. '
'10.18006/2022.10(1).144.149',
'journal-title': 'J Exp Biol Agric Sci'},
{ 'key': 'ref75',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.etap.2020.103411',
'article-title': 'Two important controversial risk factors in SARS-CoV-2 infection: '
'obesity and smoking',
'volume': '78',
'author': 'Engin AB',
'year': '2020',
'unstructured': 'Engin AB, Engin ED, Engin A. Two important controversial risk factors in '
'SARS-CoV-2 infection: obesity and smoking. Environ Toxicol Pharmacol. '
'2020, 78:103411. 10.1016/j.etap.2020.103411',
'journal-title': 'Environ Toxicol Pharmacol'},
{ 'key': 'ref76',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.mehy.2021.110741',
'article-title': 'Nicotinic receptors as SARS-CoV-2 spike co-receptors?',
'volume': '158',
'author': 'Dormoy V',
'year': '2022',
'unstructured': 'Dormoy V, Perotin JM, Gosset P, Maskos U, Polette M, Deslée G. Nicotinic '
'receptors as SARS-CoV-2 spike co-receptors?. Med Hypotheses. 2022, '
'158:110741. 10.1016/j.mehy.2021.110741',
'journal-title': 'Med Hypotheses'},
{ 'key': 'ref77',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.antiviral.2006.04.014',
'article-title': 'Emodin blocks the SARS coronavirus spike protein and '
'angiotensin-converting enzyme 2 interaction',
'volume': '74',
'author': 'Ho TY',
'year': '2007',
'unstructured': 'Ho TY, Wu SL, Chen JC, Li CC, Hsiang CY. Emodin blocks the SARS '
'coronavirus spike protein and angiotensin-converting enzyme 2 '
'interaction. Antiviral Res. 2007, 74:92-101. '
'10.1016/j.antiviral.2006.04.014',
'journal-title': 'Antiviral Res'},
{ 'key': 'ref78',
'doi-asserted-by': 'publisher',
'DOI': '10.1080/07391102.2020.1796811',
'article-title': 'Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring '
'phytochemicals: an in silico study for drug development',
'volume': '39',
'author': 'Pandey P',
'year': '2021',
'unstructured': 'Pandey P, Rane JS, Chatterjee A, Kumar A, Khan R, Prakash A, Ray S. '
'Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring '
'phytochemicals: an in silico study for drug development. J Biomol Struct '
'Dyn. 2021, 39:6306-16. 10.1080/07391102.2020.1796811',
'journal-title': 'J Biomol Struct Dyn'},
{ 'key': 'ref79',
'doi-asserted-by': 'publisher',
'DOI': '10.33263/BRIAC116.1497414985',
'article-title': 'SARS-CoV-2 spike glycoprotein as inhibitory target for Insilico '
'screening of natural compounds',
'volume': '11',
'author': 'Omoboyowa DA',
'year': '2021',
'unstructured': 'Omoboyowa DA, Balogun TA, Chukwudozie O, et al.. SARS-CoV-2 spike '
'glycoprotein as inhibitory target for Insilico screening of natural '
'compounds. Biointerface Res Appl Chem. 2021, 11:14974-85. '
'10.33263/BRIAC116.1497414985',
'journal-title': 'Biointerface Res Appl Chem'},
{ 'key': 'ref80',
'doi-asserted-by': 'publisher',
'DOI': '10.1002/ptr.7107',
'article-title': 'Silibinin as potential tool against SARS-CoV-2: in silico spike '
'receptor-binding domain and main protease molecular docking analysis, '
'and in vitro endothelial protective effects',
'volume': '35',
'author': 'Speciale A',
'year': '2021',
'unstructured': 'Speciale A, Muscarà C, Molonia MS, Cimino F, Saija A, Giofrè SV. '
'Silibinin as potential tool against SARS-CoV-2: in silico spike '
'receptor-binding domain and main protease molecular docking analysis, '
'and in vitro endothelial protective effects. Phytother Res. 2021, '
'35:4616-25. 10.1002/ptr.7107',
'journal-title': 'Phytother Res'},
{ 'key': 'ref81',
'doi-asserted-by': 'publisher',
'DOI': '10.3390/antiox10060967',
'article-title': 'N-acetylcysteine (NAC): impacts on human health',
'volume': '10',
'author': 'Tenório MC',
'year': '2021',
'unstructured': 'Tenório MC, Graciliano NG, Moura FA, Oliveira AC, Goulart MO. '
'N-acetylcysteine (NAC): impacts on human health. Antioxidants (Basel). '
'2021, 10:967. 10.3390/antiox10060967',
'journal-title': 'Antioxidants (Basel)'},
{ 'key': 'ref82',
'unstructured': 'The effect of micellized food supplements on health-related quality of '
'life in patients with post-acute COVID-19 syndrome. (2022). Accessed. '
'November 15, 2023: '
'https://clinicaltrials.gov/study/NCT05150782?cond=Long%20COVID&term=Post%20Acute%20Sequelae%20of%20COVID-19&intr=Curc....'}],
'container-title': 'Cureus',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://www.cureus.com/articles/207654-clinical-approach-to-post-acute-sequelae-after-covid-19-infection-and-vaccination',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2023, 11, 21]],
'date-time': '2023-11-21T23:22:24Z',
'timestamp': 1700608944000},
'score': 1,
'resource': { 'primary': { 'URL': 'https://www.cureus.com/articles/207654-clinical-approach-to-post-acute-sequelae-after-covid-19-infection-and-vaccination'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2023, 11, 21]]},
'references-count': 82,
'URL': 'http://dx.doi.org/10.7759/cureus.49204',
'relation': {},
'ISSN': ['2168-8184'],
'subject': ['Aerospace Engineering'],
'published': {'date-parts': [[2023, 11, 21]]}}
